Timeslots are filling quickly, apply today!
Abreos Bioscience (San Diego, CA) is a precision medicine company developing best-in-class therapeutics in Neurology, Oncology, and Autoimmune Disease. Our leading asset ABR-101 is an integrated therapeutic for Multiple Sclerosis.
Allevion Theraputics (Irvine, CA) is an early-stage company focused on the development of a wearable, non-invasive energy-based system (Allevx™) for the treatment of essential tremor (ET) This breakthrough technology has a wide range of applications including Parkinson’s Disease (PD) and dystonia.
Amnion Life (Newport Beach, CA) The AmnioBed is a highly complex device with 13 subsystems designed to ensure a safe, warm and clean environment for the most vulnerable of human beings. AmnioBed offers a patented, cost-efficient solution that can potentially substantially improve preterm infants' chances of survival, decrease long term morbidities and reduce the time needed in neonatal intensive care. AmnioBed's patented and groundbreaking incubator technology creates a simulated amniotic fluid environment to nurture and protects against two of the largest shortfalls of current technology - hypothermia and dehydration.
Bonsano Medical (California) has developed the patented fracture fixation device SIMFix®. This device uses minimally invasive side-entry intramedullary fixation. SIMFix® treats the very common osteoporotic proximal humerus fracture, the third most common fracture. Excellent clinical outcomes demonstrate surgery time reduced by half, with standard fracture surgery billing codes. Purchasing is approved at Kaiser and University of Vermont, and sale price matches or exceeds other proximal humerus fracture hardware. Clinical trial is now planned at a Level 1 academic trauma center.
Carmell Therapeutics (Pittsburgh, PA) is addressing the burden of healing with its proprietary Plasma-based Bioactive Materials (PBM) technology, designed to improve patient outcomes and reduce health care costs. Carmell’s novel approach takes whole platelet-rich plasma, processes it in a manner that retains its regenerative properties, and delivers it to the injured site in a controlled-release capacity for faster, more effective healing.
CenterMed (California) provides oral & maxillofacial surgeons with patient specific surgical accessories along with a comprehensive surgical plan. This reduces cost and operation time, keeping patients safe and happy.
Elbe Valley Medical (Dublin, Ireland) We have a patent-pending technology that we believe can be used to treat large and aggressive cancer tumours making our technology ideal for the treatment of tumours in late stage cancer patients.
Eyedaptic, Inc. (Laguna Niguel, CA) is a software technology company addressing the large unmet need in the ophthalmic field of AMD (Macular Degeneration), by developing visually assistive solutions based on open market Augmented Reality (AR) glasses and embedding our proprietary simulated natural vision software. The 178M afflicted with AMD are faced with central vision deterioration, and the most common Dry form has no existing medical cure or therapy. With a capital efficient product development model, market launch can be achieved with minimal future dilution.
gel-e (College Park, MD) is a clinical-stage medical device company developing versatile hemostatic products for surgical, medical, and consumer applications. With an initial focus on external wounds, gel-e combines the use of safe, inert ingredients with proprietary chemistry that can be designed for use across a broad spectrum of clinical applications, including vascular closure and during surgery.
Genetesis (Mason, OH) is a venture-backed medical imaging company conceived and headquartered out of Mason, Ohio. Our mission at Genetesis is to develop completely noninvasive biomagnetic imaging technologies to detect and diagnose the world’s most debilitating conditions. Our flagship product, the CardioFlux Magnetocardiograph is poised to be the most cost-effective solution for coronary artery disease detection and rule out in the emergency room.
Healionics (Seattle, WA) is addressing the critical need for improved means of dialysis access in patients with kidney failure. We have a synthetic vascular graft (artificial blood vessel) ready for human study and an exciting product pipeline, based on our platform STAR biomaterial which can improve the performance of a wide variety of implantable medical devices by preventing both infection and scarring.
iHealthScreen (iHS) Inc. (Richmond Hill, NY) has developed iPredictTM, a telemedicine-based HIPAA compliant software product to automatically screen and predict an individual at risk of developing late age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma, Cardiovascular Heart Disease (CHD) and stroke. iPredictTM will use individual’s retinal image and socio-demographic parameters and facilitate mass screening for these diseases through artificial intelligence (AI) platform and prevent blindness, death, and disability. iHS studied and recognized that the primary care doctors, Optometrists, and Ophthalmologists are the potential customers of iPredictTM. iHS will charge $50 for each patient screening which will add $100K additional revenue per year to the clinic. iHS will also make the same amount through each clinic.
Intellijoint Surgical® (Waterloo, ON develops and commercializes surgical navigation solutions. Intellijoint’s flagship product, intellijoint HIP® provides surgeons with real-time, intraoperative measurements to ensure accurate positioning of orthopaedic implants during Total Hip Arthroplasty. Intellijoint is committed to improving patients’ lives by providing every surgeon with effective, easy-to-use technology.
Laminate Medical Technologies (New York, NY) was founded in 2012 and developed VasQ - an external support device for vascular access for patients on hemodialysis. Randomized controlled clinical trials in leading European centers have shown that the technology significantly improves major outcomes. In 2017, Laminate launched a post marketing clinical program to collect additional data in conjunction with establishing commercial presence in major European countries. De Novo US study towards FDA approval in underway, including the most reputable hospitals on board. CFDA clinical trial towards market approval will be initiated in 2019, led by the Pekin University Hospital.
Moterum Technologies (South Carolina) is a medical device company whose first product, the iStrideâ, device, is a clinically proven, smart, IoT device that helps stroke survivors learn how to walk again, while fully connected to family, caregivers, and friends. Our first two clinical trials indicate we will be able to help more than 450,000 yearly stroke survivors in the United States alone, who can't walk independently. We expect commercial launch in Q3 2019, and within six months of launch we will have the world's largest gait database.
Presque Inc. (Woodside, CA) Perceived insufficient milk (PIM) is the primary reason for breastfeeding discontinuation globally. Presque is the world’s first smart bra developed to help mothers achieve their breastfeeding goals. The Presque platform is developed with independent and interactive modules for different products for different needs, including delivery of supplemental milk and monitoring of breast milk quantity, while breastfeeding. Presque’s patented platform, designed with moms’ needs in mind, is feminine, easy to use, and practical.
Pristine Surgical (Bedford, NH) has developed an integrated surgical imaging system for rigid endoscopy (arthroscopy and laparoscopy) which provides a crystal-clear HD view in a clean, low cost, hassle free single-use device.
ProSomnus (Pleasanton, CA) devices enable better therapy for people suffering from Obstructive Sleep Apnea. ProSomnus devices are comfortable and easy to use, leading to better adherence. ProSomnus devices represent a lower cost of care than incumbent Sleep Apnea therapies. Over 30 million adults have Obstructive Sleep Apnea. The vast majority remain untreated, due to the limitations of incumbent therapies. ProSomnus offers a differentiated, patented, FDA cleared solution. Tens of thousands of patients have already been treated with ProSomnus devices.
ProterixBio (Billerica, MA) is a provider of molecular assessments to transform the care of patients with chronic respiratory disease. Our initial focus is COPD, which is the 3rd leading cause of death worldwide and contributes $40B of direct healthcare spending annually in the U.S. alone. The expansion of value-based chronic care programs has created a large revenue opportunity for our first product - a COPD stratification test to identify patients for closer patient management and escalation of therapy.
Robocath (Rouen, France) designs and develops innovative robotic solutions for improving endovascular procedures. In particular, these procedures are carried out to treat vascular diseases, including heart attacks, the leading cause of death worldwide. Currently in the approval stage, the first solution developed by Robocath (R-One) will be launched early 2019 in Europe and the Middle East.
Sandstone (Livermore, CA) For medical diagnostics companies seeking to broaden access and clinical utility of plasma-based lab tests, Sandstone’s Zero-Delay Plasma Separation System is a superior replacement to blood collection tubes that immediately stabilizes pure, cell-free plasma at the point of draw. In head-to-head evaluations, the Zero-Delay System provides over 10X faster processing times and over 100X improvement in sample purity and recovery of trace analytes like cell-free DNA.
Savonix (San Francisco, CA) delivers a mobile, evidence-based assessment of cognitive and emotional function. The digital screen is a 30-minute assessment accessed from any iOS or Android device, available via a license from healthcare organizations and other third-party partners. Savonix is an accurate, accessible, actionable, and affordable tool for professional cognitive screening. This assessment empowers healthcare providers to evaluate and leverage results to improve health and treatment outcomes.
Spinal Singularity (San Clemente, CA) To address both the clinical complications and quality of life issues that plague urinary catheter users, Spinal Singularity has developed the Connected Catheter 2P, a fully internal, extended-use, urinary prosthesis that enables users to conveniently empty their bladders using a wireless controller. This puts users back in control of urination and improves quality of life.
Tivic Health Systems Inc. (Menlo Park, CA) is a bioelectronic health-tech company. We translate neuroscience into consumer-friendly medical devices for therapeutic benefit. Our first innovation, ClearUP Sinus Pain Relief, is an easy-to-use, handheld home device that delivers microcurrent waveforms. The first-of-its-kind, it's designed for the temporary relief of sinus pain for the 34+ million US sinus sufferers and 16 million with allergic rhinitis.
Vectorious Medical Technologies (Tel Aviv, Israel) The world’s first in-heart micro-computer. Vectorious is harnessing advanced AI and Machine learning technologies to provide optimal care for heart failure. The system’s technological infrastructure is based on use of the first and only sensory implant in the world that is miniature, battery-less and wireless, and that can communicate accurate readings from the heart.
Virtuoso Surgical, Inc. (Nashville, TN) The Virtuoso device uses nitinol concentric-tube technology to control multiple surgical arms and tools through a 5-8 mm rigid endoscope. The device is based on technology developed at Johns Hopkins University and Vanderbilt University by Virtuoso's President, Dr. Robert Webster, and others. The Virtuoso device is expected to be used in a myriad of endoscopic applications, including benign prostatic hyperplasia (BPH), central-airway obstructions, colloid-cyst removal in the brain, gynecologic surgeries, and other endoscopic applications. To date, the Company has been primarily funded through government grants (SBIR, STTR, and a State SBIR matching grant) and private seed capital. It is currently raising Series A funding through a preferred-share issuance.